



VTE Dublin 2020

Diagnostic and therapeutic advances in venous thromboembolism (VTE)

Friday 2nd October 2020

Mater Misericordiae University Hospital

OPENING ADDRESS: Prof Fionnuala Ní Áinle, Consultant Haematologist, MMUH/Rotunda Hospitals

SESSION 1: TBC

- 09:00-09:30 Direct thrombus imaging: the future looks bright
Dr Erik Klok: Dept of Thrombosis and Haemostasis, Leiden University Medical Centre, Leiden, The Netherlands; visiting Professor, Center for Thrombosis and Hemostasis, Mainz, Germany
- 09:30-10:00 TBC
Dr Stefano Barco, Research Group Leader Center for Thrombosis and Hemostasis University Medical Center, Mainz, Germany, Staff Physician, Clinic of Angiology, Zurich, Switzerland
- 10:00-10:30 HYPATIA: a randomised controlled trial in pregnant women with antiphospholipid antibodies
Dr Karen Schrieber, Danish Hospital for Rheumatic disease in Sonderburg, Denmark
- 10:30-11:00 **Coffee**

DR CLIVE KEARON MEMORIAL LECTURE

- 11.00-11.30 Dr Clive Kearon Memorial Lecture
The 4D Study
Dr Kerstin de Wit: Assistant Professor, Division of Emergency Medicine, Department of Medicine; Emergency Medicine and Thrombosis Physician, Hamilton Health Science, Ontario, Canada

SESSION 2: TBC

- 11:30-12:00 **Covid-19 coagulopathy and thrombosis: Novel prognostic and therapeutic opportunities: The COCOON study**
Dr Barry Kevane, Consultant Haematologist, Mater Misericordiae University Hospital, Dublin
- 12:00-12:30 VTE & Immunothrombosis; Where do we go from here?
Professor Beverley Jane Hunt OBE, Professor of Thrombosis & Haemostasis at King's College London; Consultant in the Departments of Haematology & Pathology at Guy's & St Thomas NHS Foundation Trust; & Clinical Lead in Haematological Sciences at Viapath LLP
- 12:30-13:00 COVID-19: the physician's perspective
Prof Jan Beyer Westendorf: Head of Division "Thrombosis Research", Medical Clinic III Dresden University Clinic



13:00-13:30 The Patient Experience
Ms Ann-Marie O' Neill, Thrombosis Ireland

13:30-14:00 Lunch

SESSION 3:

14:00-14:30 Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The COBRRA study
Dr Lana Castelluci, Ottawa

14.30-15:00 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)
Dr Michelle Sholzberg, Interim Division Head of Hematology-Oncology and the Medical Director of the Coagulation Laboratory at St. Michael's Hospital, Director of the Hematology-Oncology Clinical Research Group and Co-director of the Hematology-Immunology Translational Research Theme of the Li Ka Shing Knowledge Institute.

15:00-15:30 The Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (PARTUM)
Dr Leslie Skeith, Division of Hematology Department of Medicine, University of Calgary, Calgary, Canada, CanVECTOR Research Network

15:30-16:00 VTE in COVID-19: the Boston experience
Dr Rachel Rosovsky: Director, Thrombosis Research, Division of Hematology, Massachusetts General Hospital and Assistant Professor of Medicine, Harvard Medical School, Director of Thrombosis Research in Division of Hematology at MGH and Co-Chair of MGH's Thrombosis Committee. Boston.

16:00-16:30 "My personal COVID perspective" (moderated discussion)

16:30-16:45 Close

This meeting is kindly supported by the Mater Postgraduate centre with unrestricted educational support from Leo Pharma, Sanofi, BMS and Bayer